Lilly's Phase IIa migraine trial reaches primary endpoint

US drug major Eli Lilly (NYSE: LLY) announced that its investigational medicine for the prevention of migraines met its primary endpoint in a Phase IIb study in episodic migraine.

LY2951742, a CGRP-neutralizing antibody, was subject to a randomized, double-blind, placebo-controlled study which evaluated its efficacy and safety in four different doses, given in a once-monthly, subcutaneous injection in more than 400 patients with episodic migraines. This is categorized as people who experience between four and 14 migraine headache days per month.

The primary endpoint was assessing whether at least one dose of LY2951742 was superior to placebo in preventing migraine headaches. It demonstrated a statistically significant reduction in migraine headache days and a safety and tolerability profile confirming the previous results seen in a Phase IIa study.